Lack of Notable Skin Reactions from a Novel Levodopa/Carbidopa Prodrug after 10 Days of Repeated 24-Hour Continuous Subcutaneous Infusion at the Same Administration Site

被引：0

|

作者：

Facheris, M.

Qi, X.

Locke, C.

Rosebraugh, M.

Benesh, J.

机构：

来源：

MOVEMENT DISORDERS | 2019年 / 34卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

87

引用

收藏

页码：S39 / S39

页数：1

相关论文

共 3 条

[1] Ten days of 24-hour continuous subcutaneous infusion of a novel levodopa/carbidopa prodrug (ABBV-951) shows a skin safety and tolerability profile similar to saline
Facheris, M.
Qi, X.
Locke, C.
Rosebraugh, M.
Benesh, J.
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 466 - 466
[2] A Novel Levodopa/Carbidopa Prodrug (ABBV-951) 24-Hour Continuous Subcutaneous Infusion Treatment for Parkinson's Disease
Rosebraugh, Matthew
Kym, Philip
Liu, Wei
Facheris, Maurizio
Benesh, Janet
NEUROLOGY, 2019, 92 (15)
[3] Pharmacokinetics of levodopa/carbidopa prodrug (ABBV-951) 24-hour continuous subcutaneous infusion treatment for Parkinson's disease
Rosebraugh, M.
Kym, P.
Liu, W.
Facheris, M.
Benesh, J.
EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 838 - 838